{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:48:10Z","timestamp":1787507290135,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA236220"],"award-info":[{"award-number":["U01CA236220"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA188314"],"award-info":[{"award-number":["R01CA188314"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["ZIC SC 006537"],"award-info":[{"award-number":["ZIC SC 006537"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["ZIC SC 006537"],"award-info":[{"award-number":["ZIC SC 006537"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA BC 010656"],"award-info":[{"award-number":["ZIA BC 010656"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA BC 010656"],"award-info":[{"award-number":["ZIA BC 010656"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["Center of Excellence"],"award-info":[{"award-number":["Center of Excellence"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["Center of Excellence"],"award-info":[{"award-number":["Center of Excellence"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["Center of Excellence"],"award-info":[{"award-number":["Center of Excellence"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ZIE BC 011516"],"award-info":[{"award-number":["ZIE BC 011516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ZIE BC 011516"],"award-info":[{"award-number":["ZIE BC 011516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ZIE BC 011516"],"award-info":[{"award-number":["ZIE BC 011516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41591-026-04340-7","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:01:44Z","timestamp":1776330104000},"page":"2227-2237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1\/2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-4563","authenticated-orcid":false,"given":"Patrick J.","family":"Grohar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-4579","authenticated-orcid":false,"given":"Rachel","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"Wedekind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-0357","authenticated-orcid":false,"given":"Karla","family":"Ballman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7790-0777","authenticated-orcid":false,"given":"Leo","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-2528","authenticated-orcid":false,"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4233-903X","authenticated-orcid":false,"given":"Elissa A.","family":"Boguslawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna M.","family":"Gedminas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Segers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-2232","authenticated-orcid":false,"given":"Lea F.","family":"Surrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-5603","authenticated-orcid":false,"given":"Cora","family":"Ricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Klega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Navid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5852-8865","authenticated-orcid":false,"given":"Gretchen Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"The","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-9730","authenticated-orcid":false,"given":"Rebecca","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-0159","authenticated-orcid":false,"given":"Masanori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6454-3035","authenticated-orcid":false,"given":"Lindsey","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Bagatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Liza Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-8826","authenticated-orcid":false,"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-6621","authenticated-orcid":false,"given":"Brian D.","family":"Crompton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-7175","authenticated-orcid":false,"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Glod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-3138","authenticated-orcid":false,"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-7060","authenticated-orcid":false,"given":"Denise K.","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"4340_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","volume":"359","author":"O Delattre","year":"1992","unstructured":"Delattre, O. et al. Gene fusion with an ETSDNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162\u2013165 (1992).","journal-title":"Nature"},{"key":"4340_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1056\/NEJM199408043310503","volume":"331","author":"O Delattre","year":"1994","unstructured":"Delattre, O. et al. The Ewing family of tumors\u2014a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 331, 294\u2013299 (1994).","journal-title":"N. Engl. J. Med."},{"key":"4340_CR3","first-page":"429","volume":"7","author":"H Kovar","year":"1996","unstructured":"Kovar, H. et al. EWS\/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 7, 429\u2013437 (1996).","journal-title":"Cell Growth Differ."},{"key":"4340_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1525-0016(03)00101-1","volume":"7","author":"T Dohjima","year":"2003","unstructured":"Dohjima, T., Lee, N. S., Li, H., Ohno, T. & Rossi, J. J. Small interfering RNAs expressed from a Pol III promoter suppress the EWS\/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther. 7, 811\u2013816 (2003).","journal-title":"Mol. Ther."},{"key":"4340_CR5","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.1158\/0008-5472.CAN-05-0565","volume":"65","author":"S Hu-Lieskovan","year":"2005","unstructured":"Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing\u2019s sarcoma. Cancer Res. 65, 8984\u20138992 (2005).","journal-title":"Cancer Res."},{"key":"4340_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1172\/JCI119152","volume":"99","author":"K Tanaka","year":"1997","unstructured":"Tanaka, K., Iwakuma, T., Harimaya, K., Sato, H. & Iwamoto, Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing\u2019s sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99, 239\u2013247 (1997).","journal-title":"J. Clin. Invest."},{"key":"4340_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cell.2017.07.036","volume":"171","author":"G Boulay","year":"2017","unstructured":"Boulay, G. et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell 171, 163\u2013178 (2017).","journal-title":"Cell"},{"key":"4340_CR8","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-09-2261","volume":"16","author":"HV Erkizan","year":"2010","unstructured":"Erkizan, H. V., Uversky, V. N. & Toretsky, J. A. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing\u2019s sarcoma. Clin. Cancer Res. 16, 4077\u20134083 (2010).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2014.10.004","volume":"26","author":"N Riggi","year":"2014","unstructured":"Riggi, N. et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26, 668\u2013681 (2014).","journal-title":"Cancer Cell"},{"key":"4340_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.celrep.2015.01.042","volume":"10","author":"EM Tomazou","year":"2015","unstructured":"Tomazou, E. M. et al. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep. 10, 1082\u20131095 (2015).","journal-title":"Cell Rep."},{"key":"4340_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1261\/rna.078827.121","volume":"27","author":"NS Ahmed","year":"2021","unstructured":"Ahmed, N. S. et al. Fusion protein EWS-FLI1 is incorporated into a protein granule in cells. RNA 27, 920\u2013932 (2021).","journal-title":"RNA"},{"key":"4340_CR12","doi-asserted-by":"publisher","first-page":"10149","DOI":"10.1073\/pnas.0801073105","volume":"105","author":"K Gangwal","year":"2008","unstructured":"Gangwal, K. et al. Microsatellites as EWS\/FLI response elements in Ewing\u2019s sarcoma. Proc. Natl Acad. Sci. USA 105, 10149\u201310154 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4340_CR13","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1128\/MCB.26.7.2467-2478.2006","volume":"26","author":"S Kim","year":"2006","unstructured":"Kim, S., Denny, C. T. & Wisdom, R. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol. Cell. Biol. 26, 2467\u20132478 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"4340_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1101\/gr.151340.112","volume":"23","author":"S Bilke","year":"2013","unstructured":"Bilke, S. et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res. 23, 1797\u20131809 (2013).","journal-title":"Genome Res."},{"key":"4340_CR15","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1371\/journal.pmed.0040122","volume":"4","author":"K Stegmaier","year":"2007","unstructured":"Stegmaier, K. et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS\/FLI modulator in Ewing sarcoma. PLoS Med. 4, e122 (2007).","journal-title":"PLoS Med."},{"key":"4340_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/pbc.21822","volume":"52","author":"SG DuBois","year":"2009","unstructured":"DuBois, S. G. et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children\u2019s Oncology Group. Pediatr. Blood Cancer 52, 324\u2013327 (2009).","journal-title":"Pediatr. Blood Cancer"},{"key":"4340_CR17","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-14-0072","volume":"20","author":"S Sankar","year":"2014","unstructured":"Sankar, S. et al. Reversible LSD1 inhibition interferes with global EWS\/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin. Cancer Res. 20, 4584\u20134597 (2014).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR18","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nm.1983","volume":"15","author":"HV Erkizan","year":"2009","unstructured":"Erkizan, H. V. et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing\u2019s sarcoma. Nat. Med. 15, 750\u2013756 (2009).","journal-title":"Nat. Med."},{"key":"4340_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1593\/neo.101202","volume":"13","author":"PJ Grohar","year":"2011","unstructured":"Grohar, P. J. et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 13, 145\u2013153 (2011).","journal-title":"Neoplasia"},{"key":"4340_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/jnci\/djr156","volume":"103","author":"PJ Grohar","year":"2011","unstructured":"Grohar, P. J. et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J. Natl Cancer Inst. 103, 962\u2013978 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"4340_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00280-017-3382-x","volume":"80","author":"PJ Grohar","year":"2017","unstructured":"Grohar, P. J. et al. A phase I\/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS\u2212FLI1 fusion transcript. Cancer Chemother. Pharmacol. 80, 645\u2013652 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"4340_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejca.2011.09.027","volume":"48","author":"S Baruchel","year":"2012","unstructured":"Baruchel, S. et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children\u2019s Oncology Group. Eur. J. Cancer 48, 579\u2013585 (2012).","journal-title":"Eur. J. Cancer"},{"key":"4340_CR23","doi-asserted-by":"crossref","unstructured":"Reed, D. et al. Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed\/refractory Ewing sarcoma. J. Clin. Oncol. 39, 11514 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.11514"},{"key":"4340_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/cam4.3712","volume":"10","author":"A Felix","year":"2021","unstructured":"Felix, A. et al. Systematic review of phase-I\/II trials enrolling refractory and recurrent Ewing sarcoma: actual knowledge and future directions to optimize the research. Cancer Med. 10, 1589\u20131604 (2021).","journal-title":"Cancer Med."},{"key":"4340_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","volume":"77","author":"AK Larsen","year":"2016","unstructured":"Larsen, A. K., Galmarini, C. M. & D\u2019Incalci, M. Unique features of trabectedin mechanism of action. Cancer Chemother. Pharmacol. 77, 663\u2013671 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"4340_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/91008","volume":"7","author":"Y Takebayashi","year":"2001","unstructured":"Takebayashi, Y. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7, 961\u2013966 (2001).","journal-title":"Nat. Med."},{"key":"4340_CR27","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1021\/bi960306b","volume":"35","author":"Y Pommier","year":"1996","unstructured":"Pommier, Y. et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35, 13303\u201313309 (1996).","journal-title":"Biochemistry"},{"key":"4340_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1074-5521(01)00071-0","volume":"8","author":"M Zewail-Foote","year":"2001","unstructured":"Zewail-Foote, M. et al. The inefficiency of incisions of ecteinascidin 743\u2212DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 8, 1033\u20131049 (2001).","journal-title":"Chem. Biol."},{"key":"4340_CR29","doi-asserted-by":"publisher","first-page":"6449","DOI":"10.1158\/1078-0432.CCR-08-0730","volume":"14","author":"GJ Aune","year":"2008","unstructured":"Aune, G. J. et al. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin. Cancer Res. 14, 6449\u20136455 (2008).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR30","doi-asserted-by":"publisher","first-page":"13062","DOI":"10.1073\/pnas.0609877104","volume":"104","author":"DG Soares","year":"2007","unstructured":"Soares, D. G. et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl Acad. Sci. USA 104, 13062\u201313067 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4340_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano, G. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249\u2013262 (2013).","journal-title":"Cancer Cell"},{"key":"4340_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1158\/1078-0432.672.11.2","volume":"11","author":"L Lau","year":"2005","unstructured":"Lau, L. et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children\u2019s Oncology Group study. Clin. Cancer Res. 11, 672\u2013677 (2005).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR33","first-page":"3893","volume":"8","author":"K Scotlandi","year":"2002","unstructured":"Scotlandi, K. et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin. Cancer Res. 8, 3893\u20133903 (2002).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR34","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","volume":"76","author":"ML Harlow","year":"2016","unstructured":"Harlow, M. L. et al. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Res. 76, 6657\u20136668 (2016).","journal-title":"Cancer Res."},{"key":"4340_CR35","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1158\/1078-0432.CCR-18-3511","volume":"25","author":"ML Harlow","year":"2019","unstructured":"Harlow, M. L. et al. Trabectedin inhibits EWS-FLI1 and evicts SWI\/SNF from chromatin in a schedule-dependent manner. Clin. Cancer Res. 25, 3417\u20133429 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR36","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-13-0901","volume":"20","author":"PJ Grohar","year":"2014","unstructured":"Grohar, P. J. et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin. Cancer Res. 20, 1190\u20131203 (2014).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR37","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0959-8049(03)00458-1","volume":"39","author":"C Twelves","year":"2003","unstructured":"Twelves, C. et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur. J. Cancer 39, 1842\u20131851 (2003).","journal-title":"Eur. J. Cancer"},{"key":"4340_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4161\/cc.7.2.5229","volume":"7","author":"JD Hancock","year":"2008","unstructured":"Hancock, J. D. & Lessnick, S. L. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7, 250\u2013256 (2008).","journal-title":"Cell Cycle"},{"key":"4340_CR39","doi-asserted-by":"publisher","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-09-1540","volume":"69","author":"M Kinsey","year":"2009","unstructured":"Kinsey, M., Smith, R., Iyer, A. K., McCabe, E. R. & Lessnick, S. L. EWS\/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing\u2019s sarcoma. Cancer Res. 69, 9047\u20139055 (2009).","journal-title":"Cancer Res."},{"key":"4340_CR40","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1073\/pnas.0810759106","volume":"106","author":"GH Richter","year":"2009","unstructured":"Richter, G. H. et al. EZH2 is a mediator of EWS\/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl Acad. Sci. USA 106, 5324\u20135329 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4340_CR41","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/2159-8290.CD-20-1690","volume":"11","author":"HF Zhang","year":"2021","unstructured":"Zhang, H. F. et al. Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma. Cancer Discov. 11, 2884\u20132903 (2021).","journal-title":"Cancer Discov."},{"key":"4340_CR42","doi-asserted-by":"publisher","first-page":"e49819","DOI":"10.1371\/journal.pone.0049819","volume":"7","author":"MJ Camoes","year":"2012","unstructured":"Camoes, M. J. et al. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing\u2019s sarcoma and prostate carcinoma. PLoS ONE 7, e49819 (2012).","journal-title":"PLoS ONE"},{"key":"4340_CR43","doi-asserted-by":"publisher","first-page":"111761","DOI":"10.1016\/j.celrep.2022.111761","volume":"41","author":"MF Orth","year":"2022","unstructured":"Orth, M. F. et al. Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. Cell Rep. 41, 111761 (2022).","journal-title":"Cell Rep."},{"key":"4340_CR44","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.2967\/jnumed.107.046391","volume":"49","author":"JR Bading","year":"2008","unstructured":"Bading, J. R. & Shields, A. F. Imaging of cell proliferation: status and prospects. J. Nucl. Med. 49, 64S\u201380S (2008).","journal-title":"J. Nucl. Med."},{"key":"4340_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep33926","volume":"6","author":"CL Osgood","year":"2016","unstructured":"Osgood, C. L. et al. 18F-FLT positron emission tomography (PET) is a pharmacodynamic marker for EWS-FLI1 activity and Ewing sarcoma. Sci. Rep. 6, 33926 (2016).","journal-title":"Sci. Rep."},{"key":"4340_CR46","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2165\/00003088-200746100-00005","volume":"46","author":"JJ Perez-Ruixo","year":"2007","unstructured":"Perez-Ruixo, J. J. et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin. Pharmacokinet. 46, 867\u2013884 (2007).","journal-title":"Clin. Pharmacokinet."},{"key":"4340_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00280-019-03899-y","volume":"84","author":"I Poggesi","year":"2019","unstructured":"Poggesi, I. et al. Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer Chemother. Pharmacol. 84, 707\u2013717 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"4340_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/00001813-200204000-00007","volume":"13","author":"C van Kesteren","year":"2002","unstructured":"van Kesteren, C. et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13, 381\u2013393 (2002).","journal-title":"Anticancer Drugs"},{"key":"4340_CR49","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/cam4.5044","volume":"12","author":"S Attia","year":"2023","unstructured":"Attia, S. et al. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 12, 1532\u20131539 (2023).","journal-title":"Cancer Med."},{"key":"4340_CR50","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano, A. et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 446\u2013455 (2020).","journal-title":"Lancet Oncol."},{"key":"4340_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29333","volume":"68","author":"AB Collier","year":"2021","unstructured":"Collier, A. B. et al. Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: a report from the Children\u2019s Oncology Group. Pediatr. Blood Cancer 68, e29333 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"4340_CR52","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/s41416-023-02413-9","volume":"129","author":"F Duffaud","year":"2023","unstructured":"Duffaud, F. et al. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. Br. J. Cancer 129, 1940\u20131948 (2023).","journal-title":"Br. J. Cancer"},{"key":"4340_CR53","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri, G. D. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J. Clin. Oncol. 27, 4188\u20134196 (2009).","journal-title":"J. Clin. Oncol."},{"key":"4340_CR54","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1158\/1078-0432.CCR-15-2624","volume":"22","author":"CL Osgood","year":"2016","unstructured":"Osgood, C. L. et al. Identification of mithramycin analogues with improved targeting of the EWS-FLI1 transcription factor. Clin. Cancer Res. 22, 4105\u20134118 (2016).","journal-title":"Clin. Cancer Res."},{"key":"4340_CR55","doi-asserted-by":"publisher","first-page":"15207","DOI":"10.1002\/cam4.6208","volume":"12","author":"DS Shulman","year":"2023","unstructured":"Shulman, D. S. et al. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 12, 15207\u201315216 (2023).","journal-title":"Cancer Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04340-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04340-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04340-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:03:00Z","timestamp":1781791380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04340-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4340"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04340-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.G. has received honoraria for grant review and a symposium from the Pharma Mar Foundation; served as advisor for OrphAI therapeutics with options and honoraria for advisory board participation for Jazz and Inhibrx; and received support to his institution from Janssen Scientific Affairs, LLC. L.M. has received honoraria for work products from Novartis; received consultant, travel and accommodation compensation for scientific presentations from Bayer; and has uncompensated relationships with the Children\u2019s Oncology Group (COG) Foundation, the COG Research Foundation, the COG Bone Tumor Committee and the Pablove Foundation. S.G.D. has provided consulting for Bayer, Amgen, Jazz Pharmaceuticals, InhibRx, EMD Serono and Merck. R.G.M. has received consulting fees or honoraria from Boehringer Ingelheim, Deciphera, Ipsen, Physicians\u2019 Education Resource, the American Board of Internal Medicine, the American Society for Clinical Oncology and Peel Therapeutics and receives royalties from UpToDate for sarcoma-related content and stock from Peel Therapeutics for work with Peel. T.W.L. participates in consulting\/advisory boards for Advanced Microbubbles, OrphAI Therapeutics, Bayer, GlaxoSmithKline, ITM Oncologics and Jazz Pharmaceuticals and receives research support to his institution from Bayer, Pfizer, Eli Lilly and Exelixis. D.K.R. has received honoraria for advisory boards from Boehringer Ingelheim and Merck. R.C. has done advisory work for Deciphera, Recordati and Cogent Biosciences and receives royalties from UpToDate with all research support going to her institution. R.H., M.F.W., K.B., E.A.B., J.M.G., E.R.W., E.T., B.S., L.F.S., C.R., K.K., F.N., G.L., S.T., R.K., R.D.R., M.H., E.M., L.O., C.P., K.S., M.S.D., W.D.F., R.B., M.L.L., P.L.C., B.D.C., B.C.W. and J.G.G. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}